Alx Oncology Holdings (ALXO) Return on Capital Employed (2020 - 2026)
Alx Oncology Holdings recorded quarterly Return on Capital Employed of 92.55% in Q1 2026, up 58.78% quarter-over-quarter from 224.51% in Q4 2025, and up 2556.0% year-over-year from 3.48% in Q1 2025.
Alx Oncology Holdings' Return on Capital Employed history runs 7 years deep, the most recent figure standing at 92.55% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 2556.0% year-over-year to 92.55%; the TTM figure through Mar 2026 stood at 92.55% (up 2556.0% YoY), while the FY2025 annual figure was 131.91%, down 5127.0% from the prior year.
- Return on Capital Employed came in at 92.55% for Q1 2026 at Alx Oncology Holdings, up from 224.51% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 13.92% in Q3 2024 to a low of 224.51% in Q4 2025.
- A 5-year average of 73.87% and a median of 49.88% in 2023 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed surged 6414 bps in 2024 and slumped 16815 bps in 2025, its largest moves.
- Alx Oncology Holdings' Return on Capital Employed stood at 44.91% in 2022, then jumped by 62 bps to 17.29% in 2023, then tumbled by 456 bps to 96.1% in 2024, then plunged by 134 bps to 224.51% in 2025, then soared by 59 bps to 92.55% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 92.55%, 224.51%, and 182.08% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Alx Oncology Holdings | 189.80 Mn | 49.48 Mn | - | -92.55% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -92.55% |
| Dec 31, 2025 | -224.51% |
| Sep 30, 2025 | -182.08% |
| Jun 30, 2025 | -136.28% |
| Mar 31, 2025 | -118.11% |
| Dec 31, 2024 | -96.10% |
| Sep 30, 2024 | -13.92% |
| Jun 30, 2024 | -25.16% |
| Mar 31, 2024 | -20.13% |
| Dec 31, 2023 | -17.29% |
| Sep 30, 2023 | -78.07% |
| Jun 30, 2023 | -56.40% |
| Mar 31, 2023 | -49.88% |
| Dec 31, 2022 | -44.91% |
| Sep 30, 2022 | -40.34% |
| Jun 30, 2022 | -33.72% |
| Mar 31, 2022 | -26.38% |
| Dec 31, 2021 | -22.30% |
| Sep 30, 2021 | -9.75% |
| Jun 30, 2021 | -5.82% |
| Mar 31, 2021 | -4.41% |
| Dec 31, 2020 | -2.79% |
| Sep 30, 2020 | -19.12% |